enGene Therapeutics Inc. (ENGN)

NCM – Real Time Price. Currency in USD

1.75

-0.02 (-1.13%)

At close: Jun 26, 2026, 4:00 PM EDT

1.72

-0.03 (-1.71%)

After-hours: Jun 26, 2026, 6:42 PM EDT

11.06.2026

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics Inc. ("enGene" or "the Company") (NASDAQ: ENGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

08.06.2026

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics Inc. ("enGene" or "the Company") (NASDAQ: ENGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

08.06.2026

EnGene Therapeutics: The Selloff Creates An Opportunity

enGene Therapeutics is rated Buy, trading below its $4.66/share cash floor despite weak Phase 2 data for its sole asset, detalimogene voraplasmid. ENGN's therapy showed only a 25% 12-month complete response rate, underperforming competitors, but boasts a strong safety profile and Fast Track/RMAT status. Risks include FDA rejection and insurers declining coverage due to low efficacy, but current valuation implies limited further downside given the cash position.

04.06.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ: ENGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

02.06.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. (“Engene” or the “Company”) (NASDAQ: ENGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

29.05.2026

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $ENGN--ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm.

28.05.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ: ENGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Videos

No Data

There is no data to display

Press releases

11.06.2026

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

08.06.2026

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

04.06.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

02.06.2026

enGene Therapeutics Inc. (ENGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

enGene Therapeutics Inc. (ENGN)

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

EnGene Therapeutics: The Selloff Creates An Opportunity

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

Videos

No Data

Press releases

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

EnGene Therapeutics: The Selloff Creates An Opportunity

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

Videos

No Data

Press releases

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

Search stocks

enGene Therapeutics Inc. (ENGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

enGene Therapeutics Inc. (ENGN)

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

EnGene Therapeutics: The Selloff Creates An Opportunity

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

Videos

No Data

Press releases

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

EnGene Therapeutics: The Selloff Creates An Opportunity

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

Videos

No Data

Press releases

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN